WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
Pfizer Enters Into Agreement to Acquire 40 Percent Stake in Teuto in Brazil 22 October 2010
Biocon and Pfizer Enter Into Global Commercialization Agreement 20 October 2010
Results from a national survey of Alzheimer's Disease 15 October 2010
Pfizer to Acquire King Pharmaceuticals, Inc. 13 October 2010
Updated Pfizer Pipeline Focuses on Value, Unmet Medical Need 28 September 2010
Pfizer Commended For Leadership In Addressing Climate Change 22 September 2010
Pfizer to Acquire FoldRx Pharmaceuticals 02 September 2010
World Health Organization Grants Prequalification to Prevenar 13 24 August 2010
Pfizer Reports Second-Quarter 2010 Results 11 August 2010
Pfizer to Offer Free Public Access to Mental Health Assessment Tools 23 July 2010
Pfizer Strengthens Manufacturing Capabilities in Asia 13 July 2010
Pfizer Suspends Tanezumab Osteoarthritis Clinical Trial Program 25 June 2010
Phase 3 Study Showed MACUGENĀ® Improved Vision Over Standard of Care 07 June 2010
Pfizer Global Manufacturing Announces Plans to Reconfigure its Global Plant Network 20 May 2010
World Bank and Pfizer Announce Initiative to Help Improve Healthcare Delivery 26 April 2010
Pfizer Discontinues Phase 3 Trial of SutentĀ® in Advanced Hepatocellular Carcinoma 23 April 2010
Stemgent and Pfizer Announce Collaboration 16 April 2010
Pfizer Posts Details About Interactions With U.S. Physicians 01 April 2010
Pfizer Signs Long-Term Agreement to Supply Prevenar 13 to The World's Poorest Countries 24 March 2010
Pfizer Discontinues A Phase 3 Study Of Figitumumab 12 March 2010
  • Start
  • Prev
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • Next
  • End
Health data interoperability: Opportunities and threats

Business & Industry

  • Amgen successfully completes acquisition of Five Prime Therapeutics
  • GSK and Vir Biotechnology announce EMA review of dual-action monoclonal antibody VIR-7831 for the early treatment of COVID-19
  • Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%
  • Pfizer and BioNTech request regulatory agencies expand emergency use of their COVID-19 vaccine to adolescents
  • Valneva reports positive Phase 1/2 data for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001

Research & Development

  • SARS-CoV-2: New findings on the persistence of neutralizing antibodies
  • Massive fragment screen points way to new SARS-CoV-2 inhibitors
  • B.1.1.7. variant more transmissible, does not increase severity, Lancet studies suggest
  • COVID-19 causes 'unexpected' cellular response in the lungs
  • Clinical trial completion rates decline during COVID-19 pandemic
  • Study identifies possible COVID-19 drugs - including several that are FDA-approved
  • COVID-19 convalescent plasma with greater antibody levels is safe and shows promise

Conferences & Events

  • Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
  • CPhI Worldwide to return in 2021
  • Reuters Events' Cell & Gene Therapy USA
  • Total health: Build a better healthcare system
  • Don't fall for the 'next best action' trap
  • Locking down shape-shifting spike protein aids development of COVID-19 vaccine
  • COVID-19 vaccine innovation could dramatically speed up worldwide production

Regulatory Affairs

  • FDA revokes emergency use authorization for monoclonal antibody Bamlanivimab
  • Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine
  • AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets
  • Increase in vaccine manufacturing capacity and supply for COVID-19 vaccines from AstraZeneca, BioNTech/Pfizer and Moderna
  • EMA's safety committee continues investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events
  1. You are here:  
  2. Home
  3. Pfizer
  4. Pfizer completes acquisition of Therachon

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2021. All Rights Reserved.